We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

GFT505 Reduces the Risk of Cardiovascular Events

News   May 17, 2013

 
GFT505 Reduces the Risk of Cardiovascular Events
 
 
 

RELATED ARTICLES

Tucatinib Against Stage IV HER2+ Breast Cancer, Phase III Trial Results Promising

News

Study results show that the combination of the investigational drug tucatinib with standard of care treatment (including the drugs trastuzumab and capecitabine) nearly tripled one-year progression-free survival (33% vs. 12%), and nearly doubled the two-year overall survivor (45% vs. 27%) in women with HER2+ metastatic breast cancer.

READ MORE

Increasing Food Intake by Swapping Mitochondrial Genomes

News

To uncover the relationship between variation in genes and phenotypic diversity, geneticists use a set of fully sequenced fruit-fly genomes. But little is known about the variation in the mitochondrial genome, for which mutations are linked to an array of diseases. Now, EPFL scientists have created a high-resolution map of mitochondrial DNA variants in the fruit fly, connecting mitochondrial genes to metabolic traits and diseases.

READ MORE

Criteria for Cancer Clinical Trials Might Be Too Strict

News

Federal regulations may be keeping lung cancer patients out of clinical trials simply because the patients are on medications that might affect the electrical system of the heart. The regulations may be preventing al proportion of patients from participating in clinical trials.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE